Alesi Surgical are pleased to be supporting the up and coming HCSA on the 29th & 30th November 2017

Alesi Surgical are pleased to be supporting the up and coming HCSA on the 29th & 30th November 2017 in Harrogate International Centre, providing Gold standard sponsorship. We are keen to support, demonstrate and deliver on the expectations regarding developments around life sciences innovation & efficiency across the NHS. Supporting the role that procurement plays as a key enabler to the rapid adoption and diffusion of new and innovative technologies such as Ultravision. Delivering long term focus on added value which will lead for better patient outcomes, more efficient laparoscopic procedures and a safer environment within the operating room workplace.

Come and visit us on stand 12 and enjoy a workshop with Gary Welch (Director of Procurement and Supply Chain, Oxford University Hospitals NHS Foundation Trust.Programme Director, Shelford Group Procurement Programme) on “Efficiency & Innovation. How procurement can drive efficiencies and productivity in the NHS. (A case study in Laparoscopic Surgery at Oxford.)” @GaryWelch1

https://nhsprocurement.org.uk/event/2017-hcsa-annual-conference-and-exhibition/

 

HCSA1

Alesi Surgical gains crucial FDA product clearance and targets US and Asia Pacific markets

Alesi Surgical Limited, the leading innovator of minimally invasive surgery technologies, has achieved a significant milestone, receiving United States FDA clearance for its world-first Ultravision Trocar device. This follows last year’s pivotal FDA clearance of the Ultravision technology.his development follows the announcement in June 2017 of the multi-million- pound funding from its existing investors Finance Wales and IP Group, and new investors Panakes Partners and EarlyBird Venture Capital.

Following this latest achievement, and as part of the ambitious global strategy Alesi has established a US subsidiary, Alesi Surgical Technologies Inc. It is also making key appointments of new personnel to spearhead growth in North America and the Asia Pacific Rim, whilst continuing its efforts to bring the Ultravision technology to operating theatres in the UK, Europe and Middle East.

The key appointments are Charles LeDoux, US Vice President of Commercial Development, and Michael Inouye, Country Manager for Japan and Asia Pacific.

Dr Dominic Griffiths, Managing Director of Alesi Surgical, said: “We are absolutely delighted that we have received FDA clearance for the Ultravision Trocar device. This technology will make a real difference for surgeons, operating theatre staff and patients in the laparoscopic surgical field across the world.

“With FDA and other regulatory approvals in hand, it is time for Alesi to accelerate its growth. Charles LeDoux and Michael Inouye will lead the commercial activities and provide the vital inroads that will enable key clinical staff and patients to benefit from the Ultravision technology in the USA and Japan, as is already the case in Europe and the Middle East.”

The UltravisionTM system is the world’s first use of electrostatic technology to clear the vapour and particulate matter – so called “surgical smoke” – that is generated by modern surgical cutting instruments during abdominal keyhole (laparoscopic) surgery.

By integrating its technology with a trocar, the company has expanded its range of Ultravision consumables. Trocars are the devices used to access the abdominal cavity and typically 3-5 trocars are used in each of the millions of laparoscopic procedures performed worldwide each year.

Charles LeDoux, who has developed multi-million-dollar sales operations within the US medical device sector, whilst Vice President of Sales for Conmed Corporation, said: “Having worked for some of the world’s finest and best known medical device and healthcare companies, I’ve been looking for a product that improves the outcome of a patient’s surgery, enhances the surgeons’ technique and finally satisfies the economic challenges faced by the industry. The Ultravision technology is the first product I’ve come across that genuinely meets all these three criteria without question.”

Michael Inouye, who has many years’ experience of setting up and implementing multi-million-pound medical device distribution networks in Japan and across Asia, said: “I am really excited at the prospect of delivering the pioneering Ultravision technology to this part of the world. The Japanese laparoscopic (minimally invasive surgery) sector is one of the most mature markets of its type anywhere, second only to the United States in scale.

“Japan therefore is a key area of focus but we will also be looking to target South Korea and Taiwan as they too have been practicing laparoscopic techniques for many years and have sizable domestic markets as a result.”

The revolutionary Ultravision technology produces a low-energy electrostatic charge and can greatly improve visibility for surgeons by actively eliminating surgical smoke as it is created by the cutting instrument. Improving surgeons’ visibility improves the safety of the procedure, whilst minimising healthcare professionals’ exposure to surgical smoke is increasingly important worldwide because of concerns over the health risks of long-term exposure.

The technology also benefits the patient because it minimises the amount of cold, dry carbon dioxide gas – used to create a working space inside the abdomen – that a patient is exposed to during the keyhole procedure.  Excessive use of carbon dioxide contributes to cardiovascular problems, complications in anesthesia, post-surgical pain and longer recovery time for the patient.

Surgeons across the UK have confirmed the Ultravision technology as facilitating the advancement of keyhole surgery and helping to improve patient outcomes.

For more information, contact James Barton at 2B Communications Limited on 07955 227046 or james@2bcommunications.co.uk

Notes to editors

  1. Alesi Surgical founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), has developed and commercialised Ultrasounds, the world’s first system that eliminates laparoscopic surgical smoke without the need for gas exchange.

Alesi Surgical raises €6m (£5.2m) to accelerate commercialisation of breakthrough product Ultravision

 

Alesi Surgical Limited, the leading innovator of minimally invasive surgery technologies – including the world-first Ultravision device – has successfully raised a further €6m (£5.2m) funding from both new and existing investors.

The new investment comes from two leading med tech European venture capital firms, Panakes Partners and Earlybird, with continued support from Alesi Surgical’s existing shareholders, IP Group plc and Finance Wales Limited.

The funds raised will be used to drive commercial expansion of both Alesi Surgical and Ultravision into the United States and other key markets worldwide, and to undertake additional research and development around the new Ultravision technology.

Alesi Surgical also announces the appointment of three new directors, strengthening its board with key expertise to take the company and its products forward. Joining as non-executive director Phil Cooper previously President at Molnlycke Healthcare, is a recognised leader in global commercialisation and growth of privately owned companies in the med tech sector.

As part of the investment Mr Thom Rasche, Partner at Earlybird and previously Vice President Europe of Ethicon Endosurgery; and Mr Alessio Beverina, Founding Partner at Panakes Partners, will both join the board as investor directors.

Dr Dominic Griffiths, Managing Director of Alesi Surgical said: “Earlybird and Panakes are two highly respected European venture capital companies and in such a competitive funding environment their interest in Alesi and UltravisionTM speaks volumes for our potential. With the three new additions to the board we have expanded our expertise in this market and having four corporate investors places us in a strong position for future growth.”

The funds have been raised following the recent approval of the company’s leading proprietary technology platform, UltravisionTM, by both the US FDA (Food and Drug Administration) and Japanese Ministry of Health, and the commercial traction it is already gaining in already approved markets in Europe and the Middle East.

The UltravisionTM system is the world’s first use of electrostatic technology to clear the vapour and particulate matter – so called “surgical smoke” – that is generated by modern surgical cutting instruments during abdominal keyhole (laparoscopic) surgery.

The revolutionary medical device produces a low-energy electrostatic charge and can greatly improve visibility for surgeons by actively eliminating surgical smoke as it is created by the cutting instrument. Minimising healthcare professionals’ exposure to surgical smoke is increasingly important worldwide because of concerns over the health risks of long-term exposure.

The technology also benefits the patient as it minimises the amount of cold, dry carbon dioxide gas – used to create a working space inside the abdomen – that a patient is exposed to during the keyhole procedure. Excessive use of carbon dioxide contributes to cardiovascular problems, complications in anesthesia, post-surgical pain and longer recovery time for the patient.

Thom Rasche, Partner of Earlybird, said: “Obscuring of the surgical view during the laparoscopic procedure is not only cumbersome to surgeons but adds an additional risk to the safety of the procedure and to the staff being exposed to the smoke. Alesi has developed a fabulous, simple and very effective solution to help address these risks.”

Alessio Beverina said: “I am delighted to support the Alesi development. Its unique patented technology is a smart and simple solution for a real problem for laparoscopic surgeons and nurses in the operating room, both in standard and robotic operations. Whilst Alesi’s Research and Development product pipeline promises to be a game changer in the sector.”

Notes to editors:

For more information, contact James Barton at 2B Communications on 07955 227046 or james@2bcommunications.co.uk

  1. Alesi Surgical develops and commercialises products that improve the safety, efficiency and outcomes of advanced surgical procedures.
  1. The company was founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), with the vision of becoming a world leader in surgical devices. Part of Cardiff University, WIMAT runs multi-disciplinary training courses across a range of surgical and medical specialties and is the busiest multi-disciplinary training centre in the United Kingdom.
  1. For more information, visit alesi-surgical.com
  1. Alesi Surgical is based at Cardiff Medicentre,the dedicated medical, healthcare, and life sciences business incubator located on the University Hospital of Wales campus. The latter is also home to Cardiff University’s School of Medicine.  Cardiff University is Wales’s leading Higher Education Institution for innovation, ranked 7th in the UK and 45th in Europe for innovation by Thomson Reuters.
  1. Finance Wales was established by the Welsh Government in 2001 and provides commercial funding to small and medium-sized businesses throughout Wales to enable them to realise their potential for innovation and growth. The company is part of the Finance Wales Group and in 2015-16 the Group invested £63 million through 268 debt-equity investments in growing businesses. The Finance Wales Group, one of the UK’s largest SME investors, has in excess of £990 million of funds under management across all SME investment fund and the Help to Buy – Wales scheme. The Group has invested more than £484 million through more than 4,018 investments.
  1. IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiary IP Capital), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in approximately 100 early-stage to mature businesses across four main sectors — Biotech, Cleantech, Healthcare and Technology. The Company is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.
  1. About Panakes Partners

Panakès Partners is a Venture Capital investor that finances medical companies, early stage startup and SMEs, with extremely promising products and great ambition, in Europe and Israel, improving both patient outcomes and healthcare economics. Investments focus on the medical device, diagnostics and healthcare IT fields. Panakès Partners is headquartered in Milan, Italy. www.panakes.it.

  1. About Earlybird

Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company. Amongst the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support as well as access to an international network and capital markets. With over EUR 850 million under management, six IPOs and 22 trade sales, Earlybird is one of the most successful venture capital firms in Europe.

For further information: www.earlybird.com, Twitter: http://www.twitter.com/EarlybirdVC.LinkedIn: www.linkedin.com/company/earlybird-venture-capital or Facebook: www.facebook.com/EarlybirdVC

 

Alesi Surgical attending “British Society of Gynaecological Endoscopy Annual Scientific Meeting 2017” 18th – 19th May, Hull

Alesi Surgical, manufacturer of the revolutionary Ultravision laparoscopic visual field clearing system, is delighted to be supporting this year’s BSGE AGM Meeting being held at Hull City Hall.

The theme of this year’s meeting is ‘Where are we now and where are we going……’

We are looking forward to discussing with existing and future users of Ultravision how it is providing benefits to patients, operating theatre personnel and hospitals when used in Gynaecology and other laparoscopic procedures.  Ultravision is the only technology that manages surgical smoke and plume without gas filtration or exchange, thereby maximising surgical efficiency whilst minimising patient exposure to carbon dioxide.

The full agenda can be found here:

http://www.bsge2017.org/programme/

 

BSGE LogoASM 17

 

Alesi Surgical attending RSM President’s teaching day “Human factors and training – the rewards and pitfalls of a surgical career” on Friday 7th April 2017.

Alesi Surgical, manufacturer of the revolutionary Ultravision laparoscopic surgical smoke handling system, is delighted to be attending this year’s RSM President’s teaching day “Human factors and training – the rewards and pitfalls of a surgical career” being held at Frimley Park Hospital NHS Trust in Surrey.

The aim of the meeting is to explore issues in the modern era of surgical training and how trainees can get the most out of what is being provided.  The meeting will also cover human factors and how to cope when things go wrong.  It will be of value to consultants and trainees and provide an insight into some of the challenges they face now and are likely to face in the future.

The organising committee has secured a faculty of highly acclaimed speakers.  Whilst the focus is on colorectal surgery and training this meeting will be of interest to anyone with an interest in how human factors can influence clinical practice and surgical training.

We are looking forward discussing with existing and future users of Ultravision how it is providing benefits to patients, operating theatre personnel and hospitals.

The full agenda can be found here:

https://www.rsm.ac.uk/events/events-listing/2016-2017/sections/coloproctology-section/coh04-presidents-teaching-day-human-factors-and-training-the-rewards-and-pitfalls-of-a-surgical-career.aspx

Alesi Surgical attending “Controversies in Hernia Surgery” – 1st & 2nd March 2017

Alesi Surgical, the manufacturer of the revolutionary UltravisionTM laparoscopic surgical smoke handling system, is delighted to be attending this year’s 3rd “Controversies in Hernia Surgery” meeting being held at the Stoke-by-Nayland Hotel, Colchester, UK.

After two very successful meetings in 2015 and 2016 the organisers expect the 3rd International Controversies in Hernia Surgery to be a meeting not to miss. It has a busy agenda with highly recognised international and national faculty.  Topics to be discussed include new developments on hernia surgery, management of chronic pain and emergency surgery are all featured and, new this year is a debate and an MDT. Short papers and keynote lectures complete the line-up.

We are looking forward discussing with existing and future users of Ultravision how it is providing benefits to patients, operating theatre personnel and hospitals when used in hernia and other general surgery laparoscopic procedures.

The full agenda can be found here:

 

http://www.icenicentre.org/3rd-international-controversies-in-hernia-surgery-conference/

 

HerniaIceni

Alesi Surgical at 7th Annual BIARGS Conference in Leicester 1st – 3rd March

Alesi Surgical, manufacturer of the revolutionary UltravisionTM surgical smoke handling system, is delighted to be attending and sponsoring the 7th Annual British & Irish Association of Robotic Gynaecological Surgeons (“BIARGS”) Conference in Leicester this week.

BIARGS brings together surgeons interested in developing gynaecological robotic surgery for benign conditions (such as endometriosis), performing hysterectomy and pelvic floor surgery, and for the management of malignant disease, specifically radical pelvic and lymph node dissections.

Speakers include international experts on ergonomics, simulation and training, bariatrics and clinical trials.  We are looking forward to a full agenda which is exploring all aspects of setting up a robotic service in gynaecology and to discussing with existing and future users how Ultravision provides benefits to patients, operating theatre personnel and hospitals when used in robotic surgery.

Alesi Surgical pioneering surgical device gains United States FDA approval

Alesi Surgical Limited, the leading innovator of minimally invasive surgery technologies has successfully secured FDA (Food and Drug Administration) approval for its Ultravision™ system.

The Ultravision™ system is a world first that clears the vapour and particulate matter generated by modern surgical cutting instruments during abdominal keyhole (laparoscopic) surgery through the use of electrostatic technology. The technology dramatically and effortlessly improves visibility for surgeons that is otherwise rapidly obscured by this “plume” or “surgical smoke”.

“We are thrilled to have gained FDA approval for our Ultravision™ system that will now allow us to enter the US market. Commercially the US represents approximately fifty per cent of the global medical device market and so it is difficult to overstate the importance of this for the company,” said Dr Dominic Griffiths, Managing Director of Alesi Surgical.

Alesi Surgical becomes a member of a select group of only 26 medical device companies worldwide in the last 12 months that have successfully navigated the FDA De Novo regulatory review process.

The Ultravision™ system, which produces a small, low-energy electrostatic charge similar to the principal of static electricity, is able to greatly improve visibility for surgeons by actively getting rid of surgical ‘smoke’.

The technology also benefits the patient as it minimises the amount of cold, dry carbon dioxide gas – used to create a working space inside the abdomen – which a patient is exposed to during the keyhole procedure. It is not uncommon for abdominal keyhole procedures to require several hundred litres of this gas to clear the visual field throughout the procedure. Excessive use of carbon dioxide contributes to post-surgical pain and prolongs recovery time for the patient.

FDA approval is a significant milestone on the road to the company gaining traction in a global market worth an estimated £800m per year and forms part of the strategic growth of the business that has also seen the appointment of a UK national sales team.

Dr Griffiths said: “Gaining FDA approval for Ultravision™ allows us to continue the progress and development in the US market. This is the next step after launching our new Ultravision Trocar product in Europe which integrates the benefits of Ultravision™ into a pen-like access device, used in over seven million abdominal keyhole procedures performed annually, worldwide. The combination of these two major achievements places us in a strong position to enter 2017 with confidence.”

Alesi Surgical launched in 2009 as a spin out from the internationally recognised Welsh Institute of Minimally Invasive Surgery, part of Cardiff University.  To date, Alesi has secured £6.1m worth of venture capital funding, principally from its lead investors IP Group PLC and Finance Wales Limited.

Phil Barnes of Finance Wales said, “We are delighted with the progress Alesi is making and gaining this FDA clearance provides a cornerstone for their future success. We are pleased to support Alesi as they enter the US market and look forward to further growth of this innovative Welsh company.”

 

 

Notes to editors:

For more information, contact James Barton at 2B Communications

Tel: 07955 227046

International dial ++44 7955 227046

Email:  james@2bcommunications.co.uk

  1. Alesi Surgical develops and commercialises products that improve the safety, efficiency and outcomes of advanced surgical procedures.
  1. The company was founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), with the vision of becoming a world leader in surgical devices. Part of Cardiff University, WIMAT runs multi-disciplinary training courses across a range of surgical and medical specialties and is the busiest multi-disciplinary training centre in the United Kingdom.
  1. For more information, visit alesi-surgical.com
  1. Alesi Surgical is based at Cardiff Medicentre,the dedicated medical, healthcare, and life sciences business incubator located on the University Hospital of Wales campus. The latter is also home to Cardiff University’s School of Medicine.  Cardiff University is Wales’s leading Higher Education Institution for innovation, ranked 7th in the UK and 45th in Europe for innovation by Thomson Reuters. 
  1. Finance Wales was established by the Welsh Government in 2001 and provides commercial funding to small and medium-sized businesses throughout Wales to enable them to realise their potential for innovation and growth. The company is part of the Finance Wales Group and in 2015-16 the Group invested £63 million through 268 debt-equity investments in growing businesses. The Finance Wales Group, one of the UK’s largest SME investors, has in excess of £990 million of funds under management across all SME investment fund and the Help to Buy – Wales scheme. The Group has invested more than £484 million through more than 4,018 investments.
  1. IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiary IP Capital), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in approximately 80 early-stage to mature businesses across four main sectors — Biotech, Cleantech, Healthcare and Technology. The Company is listed on the Main Market of the London Stock Exchange under the code IPO.

     For more information, please visit our website at www.ipgroupplc.com.

 

Alesi Surgical Announces Japanese Regulatory Approval for Ultravision and Exclusive Agreement with Adachi Co., Ltd.

Alesi Surgical, a leading innovator of advanced minimally invasive surgery technologies, and Adachi Co., Ltd. today announce regulatory approval of the Ultravision™ visual field clearing system by the Japanese Ministry of Health, Labour and Welfare and an exclusive agreement in Japan.

Adachi Co., Ltd. was founded as a family-owned medical and scientific products distributor in 1931.  It has since grown into a leading distributor of innovative medical devices with sales, marketing and services capabilities throughout Japan.  Adachi has successfully established relationships with leading hospitals and medical organizations across the country and has deep expertise in the field of laparoscopic surgery gained through previous and current distribution of products for leading companies such as Olympus and Intuitive Surgical.

Under the terms of the agreement, which were not disclosed, Adachi will be responsible for the sales, marketing and distribution of the UltravisionTM system across Japan.  Adachi officially launched Ultravision at the The 29th Annual Meeting of the Japan Society for Endoscopic Surgery, which was held between December 8th and 10th 2016 at Yokohama, Japan.

“We are delighted to have obtained approval for the Ultravision system in Japan and entered into this comprehensive distribution partnership with Adachi Co., Ltd.” said Dominic Griffiths, Managing Director of Alesi Surgical. “Adachi has proven to be exceptionally adept at selling laparoscopic surgery products in Japan and it has a long history of success with cutting-edge technology.  We look forward to a highly successful partnership.”

“Japanese physicians and hospitals have embraced cutting-edge technologies to improve patient care and healthcare economics,” said Mr. Saburo Adachi, President and CEO of Adachi Co., Ltd.  “Ultravision’s unique mode of action effortlessly and unobtrusively eliminates surgical smoke particles from the operative visual field without the need for carbon dioxide exchange.”

Alesi Surgical Ltd at the 2016 ALSGBI Annual Scientific Meeting from Thursday 10th November until Friday 11th November – Come and meet us on Stand 5

Read more